NCT03979066View on ClinicalTrials.gov

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

November 3, 2019

Study Completion Date

November 3, 2019

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Atezolizumab

840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.

DRUG

PEGPH20

PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.

Trial Locations (1)

10032

Columbia University, New York

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Halozyme Therapeutics

INDUSTRY

lead

Gulam Manji

OTHER